Hemostasis, inflammation and cardiovascular disease

Clinical Laboratory

Volumn 48, Issue 9-10, 2002, Pages 463-470

  Páramo, José A ^a   Orbe, Josune ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; APOLIPOPROTEIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8C; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; FIBRINOLYTIC FACTOR; FIBRINOPEPTIDE A; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN C; PROTEIN S; PROTHROMBIN; SERUM AMYLOID A; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEMOSTASIS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LEUKOCYTE; MALE; MONOCYTE; PATHOGENESIS; RECURRENCE RISK; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HEMOSTASIS; HUMANS; INFLAMMATION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0036400304     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001;85:584-595.
2. Folsom AR. Haemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemostas 2001;86:366-373.
3. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombosis. Blood 2000; 95:1517-1532.
4. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001;161:2433-2439.
5. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999;340:115-126.
6. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Metaanalyses of prospective studies. J Am Med Assoc 1998;279:1477-1482.
7. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update. Arterioscler Thromb Vasc Biol 1999;19:1368-1377.
8. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-537.
9. Heinrich J, Balleisen L, Schulte H, van de Loo J, Kienast J, Wu KK, et al. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-59.
10. Cooper JA, Miller GJ, Bauer KA, Morrisey JH, Meade TW, Howarth DJ, et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000;102:2816-2822.
11. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999;100:736-742.
12. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997;17:3321-3325.
13. Rifón J, Páramo JA, Prósper F, Collado MT, Sarrá J, Rocha E. Thrombin-antithrombin complexes and prothrombin fragment 1+2 in aorto-coronary bypass surgery: relation to graft occlusion. Hematologic Path 1994;8:35-42.
14. López Y, Paloma MJ, Rifón J, Cuesta B, Páramo JA. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999;94:95-101.
15. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
16. Páramo JA, Colucci M, Collen D, van der Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J. 1985;291:573-574.
17. Rocha E, Páramo JA. The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. Fibrinolysis 1994;8:294-303.
18. Rifón J, Páramo JA, Panizo C, Montes R, Rocha E. The increase of plasminogen activator inhibitor is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Br J Haematol 1997;99:262-267.
19. Páramo JA, Panizo C, Montes R, Orbe J, Alegría E, Martínez-Caro D, et al. Markers of fibrinolytic potency and clotting activation in stable angina pectoris: assessment of atrioventricular differences and correlation with coronary patency. Fibrinolysis & Proteolysis 1999;13:133-138.
20. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-2522.
21. Cessari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol 1999; 19:1378-1386.
22. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res. 2001;103 (Suppl 1):S7-19.
23. Páramo JA, Orbe J, Fernández J. Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings. Thromb Haemostas 2001;86:636-639.
24. Montes R, Páramo JA, Angles-Cano E, Rocha E. Development and clinical application of plasmin-α2-antiplasmin complexes in plasma. Br J Haematol 1996;92:979-985.
25. Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischemic heart disease in the Caerphilly Study. Thromb Haemost 1998;79:129-133.
26. Danesh J, Whincup P, Walker M, Lennon L, Thompson A, Appleby P, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001;103:2323-2327.
27. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharret AR, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:493-498.
28. Meade TW, Cooper JA, Miller GJ. Platelet counts and aggregation measures in the incidence of ischemic heart disease (IHD). Thromb Haemost 1997;78:926-929.
29. Boekholdt SM, Bijsterveld NR, Moons AHM, Levi M. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review. Circulation 2001;104:3063-3068.
30. Blake GJ, Schmitz C, Lindpaintner K, Ridker PM. Mutation in the promoter region of the β-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. 2001;22:2262-2266.
31. Iacovello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998;338:79-85.
32. Li Y-H, Chen J-H, Wu H-L, Shi G-Y, Huang H-C, Chao T-H, et al. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am J Cardiol 2000;85:8-12.
33. Souto JC, Almasy L, Borrell M, Garí M, Martínez E, Mateo J, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000;101:1546-1551.
34. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000;83:822-825.
35. Muszbek. Deficiency causing mutations and common polymorphisms in the Factor XIII-A gene. Thromb Haemost 2000;84: 524-527.
36. Murata M, Kawano K, Matsubara Y, Ishikawa K, Watanabe K, Ikeda Y. Genetic polymorphisms and risk of coronary artery disease. Semin Thromb Hemost 1998;24:245-250.
37. Mikkelson J, Perola M, Wartiovaara U, Peltonen L, Palotte A, Penttïla A, Karhunen PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb Haemost 2000;84:78-82.
38. Iacovello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a metaanalysis. Thromb Haemost 1998;1029-1030.
39. Aleksic N, Juneja H, Folsom AR, Ahn C, Boerwinkle E, Chambless LE, et al. Platelet P1A2 allele and incidence of coronary heart disease. Results from the atherosclerosis risk in communities (ARIC) study. Circulation 2000;102:1901-1905.
40. Di Castelnuovo A, De Gaaetano G, Donatti MB, Iacovello. Platelet glycoprotein IIIa receptor polymorphism P1A1/P1A2 and coronary risk: a metaanalysis. Thromb Haemost 2001;85:626-633.
41. Roest M, Banga JD, Grobbee D, de Groot PG, Sixma JJ, Tempelman MJ. Homozygosity for 807T polymorphism in α2β1 is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000;102:1645-1650.
42. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000;7:284-289.
43. Cambien F, Poirier O, Lecerf L, Evans A, Cambon JP, Arveiler D, et al. Deletion polymorphism at the angiotensin-converting enzyme gene is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
44. Fowkes FG, Connor JM, Smith FB, Wood J, Donna PT, Lowe GD. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992;339:693-696.
45. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor on the risk of myocardial infarction. Lancet 1994;344:910-913.
46. Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schatte S, et al. E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet 1994;3:1935-1937.
47. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995;96:1664-1671.
48. Froost P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
49. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: a metaanalysis. Arterioscler Thromb Vasc Biol 1996;1250-1255.
50. Cambien F. Genetic prediction of myocardial infarction. Blood Coag Fibrinol 1999; 10 (Suppl 1):S23-S24.
51. Páramo JA, Beloqui O, Diez J. Atherosclerosis. Is it time for a new name?. Circulation 2001; 104:e38 (letter).
52. Ridker PM. Role of inflammatory biomarkers in the prediction of coronary heart disease. Lancet 2001;358:946-948.
53. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-771.
54. 2 predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-1284.
55. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta. O, Walker M, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358:971-975.
56. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. Effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001;286:2107-2113.
57. Yeh ETH, Anderson V, Pasceri V, Willerson JT. C-reactive protein. Linking inflammation to cardiovascular complications. Circulation 2001;104:974-975
58. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy subjects. N Engl J Med 1997;336:973-979.
59. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
60. Mansur AP, Annichino-Bizzachi J, Favaroto D, Avakian SD, César LAM, Ramires JAF. Angiotensin-converting enzyme and apolipoprotein B polymorphisms in coronary artery disease. Am J Cardiol 2000;85:1089-1093.
61. Raurama R, Väisänen SB, Luong L-A, Schmidt-Trücsäss A, Penttilä IM, Bouchard C, et al. Stromelysin-1 and interleukin-6 promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2657-2662.
62. Hingorani AD. Polymorphisms in endothelial nitric oxide synthase and atherogenesis. Atherosclerosis 2000;154:521-527.
63. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102:2165-2168.
64. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000;101:1785-1791.
65. Libby P, Simon DI. Inflammation and thrombosis. The clot thickness. Circulation 2001;103:1718-1720.
66. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, et al. Tissue factor expression in human arterial smooth muscle cells: TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997;100:2276-2285.
67. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complications by ligation of CD-40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96: 396-399.
68. Furman MI, Benoit SE, Barnard M, Valeri CR, Borbone ML, Becker RC, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358.
69. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-56.
70. Ridker PM, Rifai N, Clearfield M, Downs JR, Weiss JS, Miles JS, et al. Measurement of C- reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.